antiviral-agents

Documents about antiviral-agents

• Ocoxin oral solution demonstrates antiviral properties in cellular models#287864Gestión del Repositorio Documental de la Universidad de Salamanca
• "Metal-based compounds in antiviral and Antiparasitic research: Mechanistic insights from HIV NCp7 and leishmaniasis case studies".#190383PubMed
• Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C#849120ClinicalTrials.gov
• Synthesis and characterization of new HIV-1 antiviral agents#651452Dipòsit Digital de la Universitat de Barcelona
• Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection.#327635Repisalud
• Polyphenols as Antiviral Agents: Their Potential Against a Range of Virus Types#318948HAL (France)
• Antiviral Long Acting Drugs Landing in People Living With HIV#1195504ClinicalTrials.gov
• Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection#1094795ClinicalTrials.gov
• Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.#1446241ClinicalTrials.gov
• Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents#330316HAL (France)
• Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants#1102773ClinicalTrials.gov
• An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C#1153667ClinicalTrials.gov
• Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products#833901ClinicalTrials.gov
• Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis#1383042ClinicalTrials.gov
• Ribavirin Bioavailability After Telaprevir Exposure#1454557ClinicalTrials.gov
• The Mochudi Prevention Project ART Protocol#886999ClinicalTrials.gov
• Direct-Acting Antiviral Agents in Hepatitis C–Associated Indolent Lymphomas#264880IRIS
• Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients#1095537ClinicalTrials.gov
• Risk of Interstitial Lung Disease in COVID-19 Patients with Autoimmune Diseases Treated with Antiviral Agents#191545bioRxiv / medRxiv
• Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation#1212853ClinicalTrials.gov
• Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030#151807WHO IRIS
• Natural Killer Cell (CYNK-001) Infusions in Adults with AML#898774ClinicalTrials.gov
• Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA#1322489ClinicalTrials.gov
• Enriched Heparin Anti COVID-19 Trial#880523ClinicalTrials.gov
• Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B#1410323ClinicalTrials.gov
• A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients#860310ClinicalTrials.gov
• A Study of WF 10 IV Solution in Patients With Advanced HIV Disease#1294815ClinicalTrials.gov
• Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage.#631505PubMed
• Recent advances in drug discovery for Zika virus therapeutics.#18525PubMed
• A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.#682935Apollo
• PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis#1137833ClinicalTrials.gov
• The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients#1350277ClinicalTrials.gov
• The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine#884739ClinicalTrials.gov
• Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.#309484PubMed
• VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1#828958ClinicalTrials.gov
• Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS#1150858ClinicalTrials.gov
• A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis#1293993ClinicalTrials.gov
• Unraveling the role of casein kinase 2 in the SARS-CoV-2 lifecycle : Implications for host-targeted antiviral development#124513HAL (France)
• Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C#1137887ClinicalTrials.gov
• Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia#900259ClinicalTrials.gov
• Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children#1101138ClinicalTrials.gov
• Opciones terapéuticas y COVID-19: orientaciones evolutivas, 10 de noviembre de 2023#356067WHO IRIS
• Increasing competition in pharmaceutical tenders: Patents, treatment guidelines, and centralised procurement of Hepatitis C drugs in Brazil.#400691PubMed
• Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents#1212972ClinicalTrials.gov
• HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol#1282369ClinicalTrials.gov
• Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)#1484516ClinicalTrials.gov
• Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma#886850ClinicalTrials.gov
• The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients#1306842ClinicalTrials.gov
• Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers#1420360ClinicalTrials.gov
• A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons#1453132ClinicalTrials.gov